News

New data show dasiglucagon a reliable and rapid treatment in restoring plasma glucose levels.

A discussion on the uncovered benefits in risk reduction observed in patients with severe NDPR.

CDC data suggest ophthalmic patients are significantly more likely to present with a heart disease-driving condition or habit. How could preventive care improve?

An assessment of VISTA and VIVID patient data uncovered surprising risk factors associated with aflibercept success or failure in DME resolution.

Patients with nAMD, DME, and RVO received fewer intravitreal injections between pre- and post-lockdown periods.

The UCLA expert discusses the lengthy virtual agenda of this year's meeting, as well as his own session recommendations and key discussions.

Approximately 30% of schizophrenia patients do not respond to their first treatment.

These findings corroborate similar conclusions presented last year at ARVO.

Age-adjusted glaucoma blindness has nonetheless seen a downward trend between 2000 and 2020.

Andrew J. Cutler, MD discusses new research into the efficacy and safety of a D-ATS treatment in children with ADHD.

Clozapine is considered the gold standard of schizophrenia treatment.

The multidisciplinary panel of experts share final thoughts on strategies to normalize naloxone and decrease barriers to its obtainment and utilization.

Education could be the best resource in increasing prescription rates for clozapine.

The single-injection investigative gene therapy may help with providing continuous expression of aflibercept.

Data show zolpidem use in 8-week insomnia trial reduced suicidal ideation in patients, even after trial randomization ended.

The AAV8 vector–based gene therapy was associated with improvements in 2 measures of visual function.

Nearly a third of the US population has been fully vaccinated.

An FDA-approved device, provided to eligible patients with age-related macular degeneration, showed ability to detect CNV risks over 5 years.

New data show high rate of depressive symptoms in patients with NTFE schizophrenia.

The majority of patients with a treatment gap longer than 12 weeks had worsening visual acuity, notes a new ARVO study.

The SGLT-2 inhibitor, generally used for cardiometabolic and cardiovascular risk reduction, may provide similar benefits for the ophthalmic disease.

Impaired reward processing could influence the presentation of sleep disturbances for patients with ADHD.

The twice-daily oral agent is indicated for patients ≥3 years of age

Adults often do not suffer from the symptoms of hyperactivity in ADHD.

New data show adverse childhood experiences can cause personality changes proximal to trauma, rather than developing later in life.

New data show ADHD-specific text message intervention beneficial to patients who may have low rate of stimulant treatment adherence.

While treatment options do not impact 30-day readmissions, they can influence hospital length of stay and costs.

Data show effectiveness of DSRM in treating major depressive disorder with less frequent discontinuations.

More research is needed to fully understand the associations with different types of strabismus

Late life depression is a known risk factor for dementia, impacting 8-16% in the US.